Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.71 |
| ▸ | HTR2C | P28335 | 12/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2505847 | 0.82 | ALDH1A1 (0.83) | HTR2AHTR2CALDH1A1KDM4EMEN1 | |
| SCHEMBL12077352 | 0.81 | ALDH1A1 (0.93) | HTR2AHTR2CALDH1A1KDM4EMEN1 | |
| SCHEMBL4159760 | 0.78 | ALDH1A1 (1.00) | HTR2AHTR2CALDH1A1KDM4EMEN1 | |
| SCHEMBL18423593 | 0.78 | MGLL (0.73) | HTR2AHTR2CALDH1A1KDM4EMEN1 | |
| SCHEMBL8234997 | 0.77 | CACNA1B (0.54) | HTR2AHTR2CALDH1A1KDM4EMEN1 | |
| SCHEMBL13644749 | 0.76 | HTR2A (0.62) | HTR2AHTR2CALDH1A1KDM4EMEN1 | |
| SCHEMBL20399228 | 0.76 | MGLL (0.48) | HTR2AHTR2CALDH1A1KDM4EMEN1 | |
| SCHEMBL3485687 | 0.75 | ALDH1A1 (0.71) | HTR2AHTR2CALDH1A1KDM4EMEN1 | |
| SCHEMBL2896994 | 0.75 | L3MBTL3 (0.46) | SIGMAR1DRD2 | |
| SCHEMBL3485252 | 0.74 | SIGMAR1 (0.59) | HTR2AHTR2CALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791264-B2 | Benzenesulfonamide compounds and their use as blockers of calcium channels | PURDUE PHARMA L.P. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | PURDUE PHARMA L.P. (CT) | 2010-01-28 | — | — | US | disclosed |
| WO-2007118853-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | CACNA1A, CACNA1E, CACNA1B | HTR2A 499/4885HTR2C 431/4885ALDH1A1 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.